These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 9552068

  • 21. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
    Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ.
    Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
    [Abstract] [Full Text] [Related]

  • 22. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K, Kotzerke J.
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
    Lovera C, Massardo T, Galleguillos MC, González P, Comparini B, Yáñez M, Fodor M, Gil MC, Araya G, Tomicic M.
    Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Samarium for osteoblastic bone metastases and osteosarcoma.
    Anderson P.
    Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
    [Abstract] [Full Text] [Related]

  • 27. Samarium-153-EDTMP in bone metastases.
    Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkilä J, Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J.
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases.
    Tian J, Cao L, Zhang J, Ouyang Q, Hou Q, He Y.
    Chin Med J (Engl); 2002 Jun; 115(6):824-8. PubMed ID: 12123545
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE, Macey DJ, Kasi LP, Fossella FV.
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
    Serafini AN.
    Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
    Wang RF, Zhang CL, Zhu SL, Zhu M.
    Med Princ Pract; 2003 Mar; 12(2):97-101. PubMed ID: 12634464
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.